IL134271A0 - Combinations of hmg-coa reductase inhibitors and nicotinic acid compounds and methods for treating hyperlipidemia once a day at night - Google Patents
Combinations of hmg-coa reductase inhibitors and nicotinic acid compounds and methods for treating hyperlipidemia once a day at nightInfo
- Publication number
- IL134271A0 IL134271A0 IL13427198A IL13427198A IL134271A0 IL 134271 A0 IL134271 A0 IL 134271A0 IL 13427198 A IL13427198 A IL 13427198A IL 13427198 A IL13427198 A IL 13427198A IL 134271 A0 IL134271 A0 IL 134271A0
- Authority
- IL
- Israel
- Prior art keywords
- nicotinic acid
- nicotinamide
- methyl
- hmg
- combinations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US90375297A | 1997-07-31 | 1997-07-31 | |
PCT/US1998/015990 WO1999006035A2 (en) | 1997-07-31 | 1998-07-31 | COMBINATIONS OF HMG-CoA REDUCTASE INHIBITORS AND NICOTINIC ACID COMPOUNDS AND METHODS FOR TREATING HYPERLIPIDEMIA ONCE A DAY AT NIGHT |
Publications (1)
Publication Number | Publication Date |
---|---|
IL134271A0 true IL134271A0 (en) | 2001-04-30 |
Family
ID=25418027
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL13427198A IL134271A0 (en) | 1997-07-31 | 1998-07-31 | Combinations of hmg-coa reductase inhibitors and nicotinic acid compounds and methods for treating hyperlipidemia once a day at night |
IL134271A IL134271A (en) | 1997-07-31 | 2000-01-27 | Pharmaceutical compositions for altering lipids comprising nicotinic acid compounds and hmg-coa reductase inhibitors |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL134271A IL134271A (en) | 1997-07-31 | 2000-01-27 | Pharmaceutical compositions for altering lipids comprising nicotinic acid compounds and hmg-coa reductase inhibitors |
Country Status (17)
Country | Link |
---|---|
US (3) | US20040053975A1 (de) |
EP (2) | EP1792616B1 (de) |
JP (2) | JP4870869B2 (de) |
AT (2) | ATE359785T1 (de) |
AU (1) | AU752673B2 (de) |
BR (1) | BR9815548A (de) |
CA (1) | CA2298549C (de) |
CY (1) | CY1107057T1 (de) |
DE (2) | DE69837610T2 (de) |
DK (1) | DK1017390T3 (de) |
ES (2) | ES2283067T3 (de) |
HK (1) | HK1106153A1 (de) |
IL (2) | IL134271A0 (de) |
NO (1) | NO20000439L (de) |
NZ (1) | NZ520176A (de) |
PT (1) | PT1017390E (de) |
WO (1) | WO1999006035A2 (de) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IE970731A1 (en) † | 1997-10-07 | 2000-10-04 | Fuisz Internat Ltd | Product and method for the treatment of hyperlipidemia |
DE19858789A1 (de) * | 1998-12-18 | 2000-06-21 | Bayer Ag | Kombination von Cerivastatin und Fibraten |
US6569461B1 (en) | 1999-03-08 | 2003-05-27 | Merck & Co., Inc. | Dihydroxy open-acid and salts of HMG-CoA reductase inhibitors |
IL147361A0 (en) * | 1999-07-14 | 2002-08-14 | Geltex Pharma Inc | Fat-binding polymers, optionally combined with lipase inhibitors |
JP2001131151A (ja) * | 1999-11-02 | 2001-05-15 | Shionogi & Co Ltd | オレフィン誘導体の新規用途 |
IL139450A0 (en) * | 1999-11-10 | 2001-11-25 | Pfizer Prod Inc | Methods of administering apo b-secretion/mtp inhibitors |
WO2001093859A1 (en) † | 2000-06-09 | 2001-12-13 | Lek Pharmaceuticals D.D. | Stable pharmaceutical product and formulation |
AU2001295991A1 (en) * | 2000-10-23 | 2002-05-06 | Sankyo Company Limited | Compositions for improving lipids in blood |
US6916849B2 (en) | 2000-10-23 | 2005-07-12 | Sankyo Company, Limited | Compositions for improving lipid content in the blood |
CA2428204A1 (en) * | 2000-11-07 | 2002-05-16 | Sankyo Company, Limited | Lipid peroxide-lowering compositions |
TWI284529B (en) * | 2000-12-18 | 2007-08-01 | Sankyo Co | A composition for lowering triglyceride |
ITMI20012366A1 (it) * | 2001-11-09 | 2003-05-09 | Farmatron Ltd | Sistemi terapeutici stabilizzati a rilascio immediato e/o modificato per la somministrazione orale di principi attivi e/o eccipienti e/o ali |
US7176310B1 (en) | 2002-04-09 | 2007-02-13 | Ucb Sa | Pyrimidinecarboxamide derivatives and their use as anti-inflammatory agents |
JP4607436B2 (ja) * | 2002-08-02 | 2011-01-05 | 第一三共株式会社 | HMG−CoAリダクターゼ阻害剤を含有する医薬組成物 |
CA2494801A1 (en) * | 2002-08-02 | 2004-02-12 | Sankyo Company Limited | Medicinal composition containing hmg-coa reductase inhibitor |
CN100415235C (zh) * | 2002-08-02 | 2008-09-03 | 三共株式会社 | 含有HMG-CoA还原酶抑制剂的药物组合物 |
SI21402A (sl) | 2003-02-12 | 2004-08-31 | LEK farmacevtska dru�ba d.d. | Obloženi delci in farmacevtske oblike |
AR041089A1 (es) * | 2003-05-15 | 2005-05-04 | Merck & Co Inc | Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas |
CA2534371A1 (en) * | 2003-08-04 | 2005-02-10 | Pfizer Products Inc. | Dosage forms providing controlled release of cholesteryl ester transfer protein inhibitors and immediate release of hmg-coa reductase inhibitors |
JP2007509965A (ja) * | 2003-10-29 | 2007-04-19 | タワコル,レイフ | Hdl及びhdl−2bレベルを高めるための組成物及び方法 |
EP2805719A1 (de) * | 2005-03-30 | 2014-11-26 | Glaxosmithkline LLC | Nicotinamidribosid und Analoge davon |
US20070014833A1 (en) * | 2005-03-30 | 2007-01-18 | Sirtris Pharmaceuticals, Inc. | Treatment of eye disorders with sirtuin modulators |
US20060292099A1 (en) * | 2005-05-25 | 2006-12-28 | Michael Milburn | Treatment of eye disorders with sirtuin modulators |
US20070149466A1 (en) * | 2005-07-07 | 2007-06-28 | Michael Milburn | Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders |
PL1919466T3 (pl) * | 2005-07-11 | 2012-05-31 | Cortria Corp | Formulacje do leczenia nieprawidłowości lipoproteinowych obejmujące statynę i pochodną metylonikotynoamidu |
KR20070063350A (ko) * | 2005-12-14 | 2007-06-19 | 주식회사종근당 | 서방형 방출층과 속방형 방출층을 포함한 고지혈증 및동맥경화를 치료를 위한 약제학적 조성물 |
CA2569776A1 (en) * | 2006-02-17 | 2007-08-17 | Kos Life Sciences, Inc. | Low flush niacin formulation |
JP5628480B2 (ja) * | 2006-03-09 | 2014-11-19 | グラクソスミスクライン エルエルシー | 医薬成分を含有するコーティングカプセル |
US8784886B2 (en) | 2006-03-09 | 2014-07-22 | GlaxoSmithKline, LLC | Coating capsules with active pharmaceutical ingredients |
WO2008023958A1 (en) * | 2006-08-24 | 2008-02-28 | Hanall Pharmaceutical Co., Ltd. | Combined pharmaceutical formulation with controlled-release comprising dihydropyridine calcium channel blockers and hmg-coa reductase inhibitors |
WO2008023869A1 (en) * | 2006-08-24 | 2008-02-28 | Hanall Pharmaceutical Co., Ltd. | Combined pharmeceutical formulation with controlled-release comprising dihydropyridine calcium channel blockers and hmg-coa reductase inhibitors |
DE102007003524A1 (de) * | 2007-01-19 | 2008-09-04 | MEDICE Arzneimittel Pütter GmbH & Co. KG | Arzneimittel zur Behandlung und/oder Prävention von Arteriosklerose |
KR100885029B1 (ko) * | 2007-02-07 | 2009-02-23 | 지엘팜텍 주식회사 | 경구투여용 서방성 삼중정제 |
WO2009016577A2 (en) * | 2007-07-27 | 2009-02-05 | Ranbaxy Laboratories Limited | A pharmaceutical composition comprising atorvastatin and niacin |
KR100949273B1 (ko) * | 2008-02-22 | 2010-03-25 | 한올제약주식회사 | 복합제제 |
WO2009104916A2 (ko) * | 2008-02-22 | 2009-08-27 | 한올제약주식회사 | 심혈관계 질환 치료용 약제학적 제제 |
US20110111021A1 (en) * | 2008-02-22 | 2011-05-12 | Hanall Biopharma Co., Ltd. | Pharmaceutical preparation |
BRPI0912842A8 (pt) * | 2008-05-20 | 2019-01-29 | Cerenis Therapeutics Holding | composição farmacêutica, métodos para prevenir ou tratar o rubor induzido por niacina em um indivíduo, para reduzir pelo menos um sintoma de rubor relacionado com a terapia com niacina em um indivíduo, para diminuir os efeitos colaterais relacionados com a protaglandina em um indivíduo, para diminuir uma taxa de descontinuação do tratamento com niacina por um indivíduo, para aumentar a submissão do paciente ao tratamento com niacina, para tratar aterosclerose em um paciente, para tratar uma doença relacionada com um perfil de hdl baixo em um paciente, formulação do ácido nicotínico de dispensação modificada, uso da composição farmacêutica, e, microcápsula de aspirina |
WO2009149056A2 (en) * | 2008-06-02 | 2009-12-10 | Dr. Reddy's Laboratories Ltd. | Combinations of niacin and an oxicam |
CN102105171A (zh) * | 2008-06-02 | 2011-06-22 | 雷迪博士实验室有限公司 | 改进释放烟酸制剂 |
US20100178341A1 (en) * | 2008-06-11 | 2010-07-15 | Ranbaxy Laboratories Limited | BILAYERED TABLET COMPRISING NIACIN AND HMG-CoA REDUCTASE INHIBITOR |
EP2310004A1 (de) * | 2008-07-11 | 2011-04-20 | Kareus Therapeutics SA | Niacinzusammensetzungen für verminderte produktion von amyloid-beta-peptid 42 (abeta 42) und zur behandlung von morbus alzheimer |
TW201041608A (en) * | 2009-05-01 | 2010-12-01 | Eurand Inc | Orally disintegrating tablet compositions comprising combinations of high and low-dose drugs |
CA2706270C (en) * | 2010-06-03 | 2020-01-07 | Accucaps Industries Limited | Pharmaceutical formulations of statins and omega-3 fatty acids for encapsulation |
ES2643693T3 (es) | 2011-05-20 | 2017-11-23 | Astrazeneca Uk Limited | Composición farmacéutica de rosuvastatina cálcica |
EP3218349A2 (de) | 2014-11-14 | 2017-09-20 | Gemphire Therapeutics Inc. | Verfahren und zwischenprodukte zur herstellung von ?,?-dicarbonäureterminierten dialkanethern |
AU2016349634A1 (en) * | 2015-11-06 | 2018-05-10 | Gemphire Therapeutics, Inc. | Treatment of mixed dyslipidemia |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3524001A (en) * | 1965-03-04 | 1970-08-11 | Upjohn Co | Compositions and method for reducing free fatty acid and cholesterol in the blood of mammals with 3,5 - disubstituted isoxazoles |
JPS63310827A (ja) * | 1987-06-15 | 1988-12-19 | Sanwa Kagaku Kenkyusho Co Ltd | ニコチン酸誘導体を主剤とする徐放性製剤 |
US5260305A (en) * | 1988-12-12 | 1993-11-09 | E. R. Squibb & Sons, Inc. | Combination of pravastatin and nicotinic acid or related acid and method for lowering serum cholesterol using such combination |
US4933165A (en) * | 1989-01-18 | 1990-06-12 | Merck & Co., Inc. | Coenzyme Q10 with HMG-CoA reductase inhibitors |
US5268181A (en) * | 1989-04-13 | 1993-12-07 | Upsher-Smith Laboratories, Inc. | Method of using niacin to control nocturnal cholesterol synthesis |
CA2016467A1 (en) * | 1989-06-05 | 1990-12-05 | Martin Eisman | Method for treating peripheral atherosclerotic disease employing an hmg coa reductase inhibitor and/or a squalene synthetase inhibitor |
CA2018470A1 (en) * | 1989-07-17 | 1991-01-17 | Scott Adams Biller | Phosphorus-containing squalene synthetase inhibitors and method |
US5591772A (en) * | 1991-11-22 | 1997-01-07 | Lipogenics, Inc. | Tocotrienols and tocotrienol-like compounds and methods for their use |
US5135935A (en) * | 1991-05-17 | 1992-08-04 | Merck & Co., Inc. | Squalene synthetase inhibitors |
US5840339A (en) * | 1991-07-30 | 1998-11-24 | Kunin; Robert | Blood cholesterol reducing pharmaceutical composition |
US5292534A (en) * | 1992-03-25 | 1994-03-08 | Valentine Enterprises, Inc. | Sustained release composition and method utilizing xanthan gum and an active ingredient |
US5609884A (en) * | 1992-08-31 | 1997-03-11 | G. D. Searle & Co. | Controlled release naproxen sodium plus naproxen combination tablet |
US6080428A (en) * | 1993-09-20 | 2000-06-27 | Bova; David J. | Nicotinic acid compositions for treating hyperlipidemia and related methods therefor |
US6129930A (en) * | 1993-09-20 | 2000-10-10 | Bova; David J. | Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night |
US6369103B1 (en) * | 1994-01-18 | 2002-04-09 | Bristol-Myers Squibb Company | Method for preventing or reducing risk of onset of cardiovascular events employing an HMG CoA reductase inhibitor |
US5582838A (en) * | 1994-12-22 | 1996-12-10 | Merck & Co., Inc. | Controlled release drug suspension delivery device |
EP0821587A4 (de) * | 1995-04-19 | 1999-05-19 | Lipoprotein Technologies Inc | Mittel, kits und verfahren zur verabreichung von antilipämischen und gegen die blutplättchen-aggregation wirkenden arzneistoffen |
US5773453A (en) * | 1995-04-19 | 1998-06-30 | Vanderbilt University | Methods for administration of antilipemic drugs |
-
1998
- 1998-07-31 EP EP07003276A patent/EP1792616B1/de not_active Expired - Lifetime
- 1998-07-31 DK DK98938228T patent/DK1017390T3/da active
- 1998-07-31 ES ES98938228T patent/ES2283067T3/es not_active Expired - Lifetime
- 1998-07-31 BR BR9815548-2A patent/BR9815548A/pt not_active Application Discontinuation
- 1998-07-31 DE DE69837610T patent/DE69837610T2/de not_active Expired - Lifetime
- 1998-07-31 EP EP98938228A patent/EP1017390B1/de not_active Expired - Lifetime
- 1998-07-31 CA CA002298549A patent/CA2298549C/en not_active Expired - Lifetime
- 1998-07-31 PT PT98938228T patent/PT1017390E/pt unknown
- 1998-07-31 NZ NZ520176A patent/NZ520176A/en not_active IP Right Cessation
- 1998-07-31 AU AU86801/98A patent/AU752673B2/en not_active Ceased
- 1998-07-31 AT AT98938228T patent/ATE359785T1/de active
- 1998-07-31 IL IL13427198A patent/IL134271A0/xx active IP Right Grant
- 1998-07-31 WO PCT/US1998/015990 patent/WO1999006035A2/en active IP Right Grant
- 1998-07-31 JP JP2000504849A patent/JP4870869B2/ja not_active Expired - Fee Related
- 1998-07-31 AT AT07003276T patent/ATE451926T1/de not_active IP Right Cessation
- 1998-07-31 DE DE69841395T patent/DE69841395D1/de not_active Expired - Lifetime
- 1998-07-31 ES ES07003276T patent/ES2336492T3/es not_active Expired - Lifetime
-
2000
- 2000-01-27 NO NO20000439A patent/NO20000439L/no not_active Application Discontinuation
- 2000-01-27 IL IL134271A patent/IL134271A/en not_active IP Right Cessation
-
2003
- 2003-09-02 US US10/260,027 patent/US20040053975A1/en not_active Abandoned
-
2007
- 2007-05-07 CY CY20071100604T patent/CY1107057T1/el unknown
- 2007-10-30 HK HK07111713.6A patent/HK1106153A1/xx not_active IP Right Cessation
-
2009
- 2009-02-27 US US12/394,441 patent/US20090226518A1/en not_active Abandoned
- 2009-07-22 JP JP2009170721A patent/JP2009235105A/ja active Pending
-
2011
- 2011-10-27 US US13/282,755 patent/US20120164221A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
DE69841395D1 (de) | 2010-01-28 |
DE69837610D1 (de) | 2007-05-31 |
WO1999006035A3 (en) | 1999-04-22 |
CA2298549C (en) | 2006-01-10 |
NO20000439D0 (no) | 2000-01-27 |
WO1999006035A2 (en) | 1999-02-11 |
PT1017390E (pt) | 2007-07-24 |
EP1017390A2 (de) | 2000-07-12 |
EP1792616A1 (de) | 2007-06-06 |
BR9815548A (pt) | 2000-11-07 |
JP2001511444A (ja) | 2001-08-14 |
JP2009235105A (ja) | 2009-10-15 |
CY1107057T1 (el) | 2012-10-24 |
IL134271A (en) | 2006-07-05 |
US20090226518A1 (en) | 2009-09-10 |
DK1017390T3 (da) | 2007-06-11 |
JP4870869B2 (ja) | 2012-02-08 |
EP1017390B1 (de) | 2007-04-18 |
NO20000439L (no) | 2000-03-22 |
ATE359785T1 (de) | 2007-05-15 |
US20040053975A1 (en) | 2004-03-18 |
EP1792616B1 (de) | 2009-12-16 |
DE69837610T2 (de) | 2008-01-03 |
US20120164221A1 (en) | 2012-06-28 |
HK1106153A1 (en) | 2008-03-07 |
ES2283067T3 (es) | 2007-10-16 |
CA2298549A1 (en) | 1999-02-11 |
ES2336492T3 (es) | 2010-04-13 |
ATE451926T1 (de) | 2010-01-15 |
AU752673B2 (en) | 2002-09-26 |
AU8680198A (en) | 1999-02-22 |
NZ520176A (en) | 2005-02-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL134271A0 (en) | Combinations of hmg-coa reductase inhibitors and nicotinic acid compounds and methods for treating hyperlipidemia once a day at night | |
AU5683296A (en) | N-benzylindol-3-yl propanic acid derivatives as cyclooxygena se-2 inhibitors | |
NO973814D0 (no) | Basisk stabilisert sammensetning av HMG-CoA-reduktase inhibitor | |
AU7756694A (en) | Substituted heterocyclic carboxamide esters, their preparation and their use as pharmaceuticals | |
IE970731A1 (en) | Product and method for the treatment of hyperlipidemia | |
EP3363463A3 (de) | Hyaluronsäurederivat und arzneimittel damit | |
CA2356158A1 (en) | Combinations of cholesteryl ester transfer protein inhibitors and nicotinic acid derivatives for cardiovascular indications | |
HU9202265D0 (en) | Wall-mounted disc for joining sanitary equipments onto mounting wall | |
HUT63328A (en) | Process for producing stabilized pharmaceutical compositions comprissing hmg-coa reductase inhibitor | |
EP0773022A3 (de) | Pharmazeutische Zubereitung zur Behandlung akuter Rhinitiden, enthaltend Sympthomimeticum und Pantothenol und/oder Pantothensäure | |
AU2058992A (en) | HMG-COA reductase inhibitors | |
AU3368400A (en) | Aerosol compositions of hmg-coa reductase inhibitors for inhibiting inflammationassociated with pulmonary disease | |
PL331339A1 (en) | Antihrombotic and antiarteriosclerotic pharmaceutical composition containing derivative of thiene pyridine as well as an inhibitor of hmg-coa reductase | |
GB9718903D0 (en) | Method,compositions and kits for increasing the oral bioavailability of pharmaceutical agents | |
BR0317520A (pt) | Composições de inibidores de proteìna de transferência de ésteres de colesterilo e inibidores de hmg-coa redutase | |
AU7570996A (en) | Quinoline derivatives as type iv phosphodiesterase inhibitors | |
AU4543699A (en) | Multibinding inhibitors of hmg-coa reductase | |
AU7101691A (en) | Quinoline and pyridine anchors for hmg-coa reductase inhibitors | |
AU637321B2 (en) | Quinoline and pyridine anchors for a hmg-coa reductase inhibitors | |
AU7654200A (en) | Phthalazinone derivatives as pd3/4 inhibitors | |
CA2511595A1 (en) | Optically active dihydropyridine derivative | |
AU7820598A (en) | Cembranoid inhibitors of nicotinic acetylcholine receptors | |
AU2116201A (en) | A therapeutic mixture of hmg-coa reductase inhibitors | |
AU1289792A (en) | Aminosteroids in a method for inhibiting c17-20 lyase | |
AU2806595A (en) | Pyridonecarboxylic acid derivative, ester thereof, salt thereof, and intermediate for synthesis of these compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FF | Patent granted | ||
KB | Patent renewed | ||
KB | Patent renewed |